BIOMAT Database Logo BIOMAT Database Logo

Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation. 1998

M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Third Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.

We report a case of haemophagocytic syndrome (HPS) occurring after allogeneic bone marrow transplantation (BMT) for acute promyelocytic leukaemia (APL) in a patient in fourth complete remission (CR). Anti-cytomegalovirus (CMV) antibody (Ab) was negative in this patient before BMT. BMT was performed from an HLA-identical unrelated donor who was positive for CMV Ab. After bone marrow engraftment and haematological recovery, severe acute graft-versus-host disease (GVHD) developed. This patient was treated with methylprednisolone in addition to cyclosporin A (CsA). Acute GVHD showed partial improvement, but CMV antigenaemia was observed. Despite administration of gancyclovir and immunoglobulin, CMV antigenaemia showed no improvement and HPS developed. As no other infections or malignancies were observed, we suspect that CMV infection was the trigger for development of HPS.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy.
June 1999, Bone marrow transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
February 1997, Bone marrow transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Fulminant varicella hepatitis following bone marrow transplantation.
January 1985, JAMA,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Fulminant haemophagocytic syndrome.
December 2008, Pathology,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Fulminant hepatic failure following bone marrow transplantation for hepatitis-associated aplastic anemia.
January 1990, Bone marrow transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Virus-associated hemophagocytic syndrome following bone marrow transplantation.
January 1991, The American journal of pediatric hematology/oncology,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
CMV antigenemia following bone marrow transplantation: risk factors and outcomes.
January 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Successful unrelated bone marrow transplantation for Shwachman-Diamond syndrome.
January 2001, Bone marrow transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease.
July 1997, Bone marrow transplantation,
M Sato, and T Matsushima, and S Takada, and N Hatsumi, and K Kim, and M Sakuraya, and T Saito, and J Tamura, and M Karasawa, and H Murakami, and T Naruse
Fulminant Rickettsia tsutsugamushi infection associated with haemophagocytic syndrome.
May 1994, Lancet (London, England),
Copied contents to your clipboard!